Navigation Links
Generex Provides an Overview of its Cancer Immunotherapy Product, AE37, and Potential in Early Breast Cancer Given Current and Potential Future Therapies
Date:1/30/2013

of the immune system that ensure generation of a robust and specific immune response. What makes this modification unique is that it amplifies the vaccine potency of the HER2 fragment without loosing specificity, unlike many non-specific immune stimulants. The Ii-Key modification can be added to many different 'payloads' to generate a specific and robust immune response. Given the increasing interest in cancer immunotherapy, this will be very attractive to companies wishing to 'supercharge' their specific vaccines.

The positive interim data of the AE37 trial have received particular attention given the robust and well-designed nature of the Phase IIb trial. In addition to being the only randomized, controlled and blinded study conducted with this type of HER2 targeted immunotherapy, it is also the largest vaccine therapy study conducted in the adjuvant breast cancer setting to date (330 patients). In recognition of the quality of the trial and encouraging results, the abstract reporting the interim results was recognized with a 2012 American Society of Clinical Oncology (ASCO) Merit Award bestowed by the Conquer Cancer Foundation and the 2012 Scientific Program Committee of ASCO. Further, the FDA has given the company the green light to proceed with submission of a Special Protocol Assessment for the Phase III trial.

Antigen Express is well positioned to execute on its business model, which includes potential out-licensing of additional clinical development of its lead compound in early breast cancer while pursuing additional products using its proprietary immunotherapy Ii-Key technology platform upon which AE37 is based. The advancement of AE37 in breast cancer clinical development will help to validate the company's immune technology platform. Low expression of the HER2 target is widespread among a variety of cancers including breast, prostate, ovarian, lung and cancers of the GI tract suggesting potential future areas for clinical research. Addit
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
2. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
3. Generex Augments Antigen Express Scientific Advisory Board
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
6. Generex Announces Results of Annual Stockholders Meeting
7. Generex Addresses Recent Trading Volume in Shares of its Common Stock
8. Generex Announces Details of Investor Conference Call
9. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
10. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
11. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... 2014 financial results will be released on Thursday, November ... conference call and live webcast at 1:30 p.m. PST ...
(Date:10/30/2014)... MADRID , October 30, 2014 ... build tolerance for cow milk   Cow milk protein allergy ... infants and early childhood. Until now, it has been ... Recently, it has been shown that it is possible ... in a significant number of children during the first ...
(Date:10/30/2014)... -- Electrodes are devices that convert ionic potential ... diagnose as well as treat several ailments and ... the detection of chemical reactions derived from electrical ... the patients. In addition, few electrodes such as ... perform minimally invasive surgical procedures. The electrodes for ...
Breaking Medicine Technology:BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4
... April 28, 2011 ResMed Inc. (NYSE: RMD ... ended March 31, 2011.  Revenue for the quarter ended March ... 12% increase on a constant currency basis) over the quarter ... 2011, income from operations was $64.0 million and net income ...
... Financial Highlights ($ in millions, except ... , $109.5 , 28.8% increaseTotal Net Product Revenue , ... , 24.7% increaseAldurazyme BioMarin Net Product Revenue* , $18.7 ... increaseFirdapse Net Product Revenue , $3.1 , $0.1GAAP Net ...
Cached Medicine Technology:ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 2ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 3ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 4ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 5ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 6BioMarin Announces First Quarter 2011 Financial Results 2BioMarin Announces First Quarter 2011 Financial Results 3BioMarin Announces First Quarter 2011 Financial Results 4BioMarin Announces First Quarter 2011 Financial Results 5BioMarin Announces First Quarter 2011 Financial Results 6BioMarin Announces First Quarter 2011 Financial Results 7BioMarin Announces First Quarter 2011 Financial Results 8BioMarin Announces First Quarter 2011 Financial Results 9BioMarin Announces First Quarter 2011 Financial Results 10BioMarin Announces First Quarter 2011 Financial Results 11
(Date:10/30/2014)... October 30, 2014 High efficacy ... concepts in the medical-grade skin care domain: Cosmederm, ... of uniquely potent topical dermatological products, today announces ... http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 anti-irritant technology. ... concentrations (50% and 70%) and a low pH ...
(Date:10/30/2014)... New Haven, CT (PRWEB) October 30, 2014 ... product categories are raising questions about the impact of ... as the marketing method most likely to influence a ... online research poll of 525 consumers conducted by radio ... in four product categories, isolating the results of respondents ...
(Date:10/30/2014)... 30, 2014 Home Care Assistance – ... of non-medical, in-home senior care, is weighing in on ... health. , The study, performed by the University of ... and 78 over a week-long period and observed how ... physical activity. By examining the structural soundness of the ...
(Date:10/30/2014)... October 30, 2014 USARAD ... Accredited teleradiology and specialty telemedicine solutions provider, including ... to its existing teleradiology services at Mission Bend ... and expert telemedicine services, to the state-of-the-art, 24/7, ... a result of this innovative partnership, there will ...
(Date:10/30/2014)... October 30, 2014 Victory Healthcare, ... its 2014 third quarter infection rates and patient ... infection rates of only two percent or less, ... scores exceeding 98 percent. , “We are delighted ... included rising satisfaction scores,” said Robert Helms, chairman ...
Breaking Medicine News(10 mins):Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3
... support efforts to reduce air pollution, especially diesel exhaust ... studies from Europe demonstrate the health damage done by ... engines. , An 11-year period of improving air quality ... air in Europe, produced measurable benefits in lung function ...
... healthy lifestyle drives new store openings, PITTSBURGH, Dec. ... new resolution or two. For GNC, it means more ... is expected to rise steadily,through 2012, according to the ... to once again expand its store base and overall,business: ...
... Ky., Dec. 5 Ventas, Inc. (NYSE:,VTR) ... the Executive,Compensation Committee of its Board of ... certain executive officers to encourage their,long-term retention ... to,Raymond J. Lewis, the Company,s Chief Investment ...
... Growing price competition from,low-cost manufacturers has been forcing ... profitable growth, which Kalorama Information predicts,will likely come ... pharmaceutical,medical foods, or biomedical device companies -- a ... Healthcare Opportunities for Food Ingredient,Manufacturers., Thousands of ...
... still debated, experts say , , WEDNESDAY, Dec. 5 (HealthDay News) ... Wednesday that the cancer drug Avastin should not be used ... close vote, 5-4, the advisers decided the drug,s ability to ... increased risk of blood clots and other cardiovascular troubles among ...
... A new white paper,published by The Endocrine ... major new initiatives to ensure effective,broad-based minority participation ... of recommendations to ensure that data from clinical,trials ... The white paper, developed by a special ...
Cached Medicine News:Health News:Cleaner Air Leads to Healthier Lungs 2Health News:Cleaner Air Leads to Healthier Lungs 3Health News:GNC Franchising Expected to Grow Through 2008 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 3Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 4Health News:Medical Industry Offers Food Ingredient Companies More Than One Billion Reasons to Think Healthy 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 3Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 2Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 3Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 4
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The VISULAS 532s combines ease of use, efficiency and safety to provide ophthalmologists with an overall system sharply focused on their requirements. ,The VISULAS 532s is a laser of many talent...
Two point fixation, tips separated by 13 mm. Each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with thumb catch lock and dull finish....
... 100 Hue Test including MS-Excel scoring template on ... 100 Hue Test comes boxed in clear acrylic ... potential for test disruption by holding the ... from Richmond Products includes 93 color discs, four ...
Medicine Products: